Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 3. General pharmacological properties.
D000632:Aminopyrine / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001463:Barbiturates / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D002319:Cardiovascular System / Q000187:drug effects; D003061:Codeine / Q000378:metabolism; D004231:Diuresis / Q000187:drug effects; D004487:Edema; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D008297:Male; D051379:Mice; D009420:Nervous System / Q000187:drug effects; D010435:Pepsinogens / Q000652:urine; D010653:Phenylbutazone / Q000494:pharmacology; D010672:Phenytoin / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D013729:Terpenes / Q000494:pharmacology*; D014527:Uric Acid / Q000652:urine
D000893:Anti-Inflammatory Agents; D001463:Barbiturates; D001786:Blood Glucose; D010435:Pepsinogens; D011720:Pyrazoles; D013729:Terpenes; D000632:Aminopyrine; D014527:Uric Acid; D010672:Phenytoin; D010653:Phenylbutazone; D003061:Codeine